Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 9029 results

  1. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued Reference number: GID-TA10869

    Technology appraisal guidance
    Discontinued

  2. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    Discontinued Reference number: GID-TA10937

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  4. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

    Technology appraisal guidance
    Discontinued

  5. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  6. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  7. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued Reference number: GID-TA10154

    Technology appraisal guidance
    Discontinued

  8. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued Reference number: GID-TA10325

    Technology appraisal guidance
    Discontinued

  9. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  10. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425

    Technology appraisal guidance
    Discontinued

  11. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued Reference number: GID-TA10539

    Technology appraisal guidance
    Discontinued

  12. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  13. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued

  14. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued Reference number: GID-TA10709

    Technology appraisal guidance
    Discontinued

  15. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued